Mario Saltarelli has been appointed chief medical officer of Boston-based Syntimmune. Saltarelli comes to Syntimmune from Vertex (NASDAQ: [[ticker:VRTX]]), where he was senior vice president of early development and neurology. Donald Johns, who has been acting chief medical officer of Syntimmune, will now become executive vice president of medical and scientific affairs. Syntimmune is developing antibody therapies for rare autoimmune disorders.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
